Vendor Intelligence Report: Xianhong Tong XHT Peptides

Published 13 Jun 2026. 25-page investigative report on who is behind Xianhong Tong XHT Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

XHT Peptides is a narrow, product-specific case, not a catalog-wide green light. Across 6 Finnrick lab tests the overall pass rate is 100%: 6 pass / 0 fail. That record covers Tirzepatide only, where identity and purity confirmation are a real positive signal, but the same record also contains a batch-level quantity-control warning that matters for dosing rather than ingredient identification.

The sharper adverse signal is documentation integrity. XHT’s COA page mixes in-house records with customer-feedback style reports; one displayed Chromate COA verifies to another vendor, and one displayed Janoshik Semax report shows Semax not detected with Selank present. Those are not missing-paperwork issues; they are provenance and wrong-product-document issues that change how much weight a buyer should give XHT’s public quality claims.

The accountability trail is also thinner than the Hong Kong manufacturer narrative suggests. The claimed Hong Kong technology-materials company was not verified in the supplied public-record trail, WHOIS points to Zhejiang, the site appeared as a blank Shoplazza fashion template shortly after registration, and the public contact layer reduces to Cherry, a Hong Kong mobile number, a personal Gmail, and no physical address. Reputation support is limited by on-site review-date anomalies and a Trustpilot profile removed for guideline violations.

Buyer read: XHT is most plausibly considered only for Tirzepatide, and only with lot-specific verification and conservative dosing assumptions. Non-Tirzepatide products should be treated as unverified by Finnrick, and the posted Semax evidence should not be treated as support for Semax.

Inside the full report:

  • Finnrick Tirzepatide timeline, methodology-divergence chart, and Appendix A lab data
  • COA provenance analysis for the Chromate report displayed by XHT
  • Janoshik Semax/Selank report analysis and quality-document implications
  • Corporate identity trail across Hong Kong registry leads, WHOIS, DNS, and Wayback
  • Review and reputation evidence, including Trustpilot removal and review-date anomalies
  • Payment, special-line shipping, customs-clearance, and buyer-recourse assessment

Risk assessment

  • COA provenance / third-party misrepresentation risk — high: Tirzepatide / TZ10 documentation: Chromate COA #25538 on XHT’s COA page verifies to AC Peptides, not XHT.
  • Wrong-product documentation risk — high: Semax documentation: Janoshik #61469 displayed by XHT reports Semax not detected and Selank 10.12 mg; client is a private email.
  • Tirzepatide quantity-control risk — high: Tirzepatide passed 6/6 Finnrick tests, but batch-level material flags a +32.0% overfill; direct dosing concern.
  • Corporate identity and accountability risk — medium: Claimed Hong Kong entity was not verified; WHOIS points to Zhejiang; no physical address or corporate email is visible.
  • New-storefront / history-claim risk — medium: Domain was created March 4, 2025; the next-day Wayback capture was a blank Shoplazza fashion template.
  • Untested-catalog risk for non-Tirzepatide products — medium: Finnrick’s current official record covers only Tirzepatide; Retatrutide, HGH, Tesamorelin, GHK-Cu, PEG-MGF, Snap-8, BAC, and other items lack Finnrick support.
  • Reputation and review-authenticity risk — medium: Trustpilot profile removed; on-site reviews predate domain registration; independent community feedback is minimal.
  • Payment recourse risk — medium: Bitcoin and Western Union are accepted; non-reversible channels limit buyer remedies.
  • Special-line shipping and customs risk — medium: FAQ states express special line, door-to-door including customs clearance, plus reship guarantee; buyers face seizure and disclosure risk.